High-performance liquid chromatography method for the quantification of entacapone in human plasma
- 5 September 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Chromatography B
- Vol. 823 (2), 189-194
- https://doi.org/10.1016/j.jchromb.2005.06.036
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- EntacaponeDrugs, 1999
- A Double-Blind Pharmacokinetic and Clinical Dose—Response Study of Entacapone as an Adjuvant to Levodopa Therapy in Advanced Parkinson's DiseaseClinical Neuropharmacology, 1996
- Effect of One Month's Treatment with Peripherally Acting Catechol-O-methyltransferase Inhibitor, Entacapone, on Pharmacokinetics and Motor Response to Levodopa in Advanced Parkinsonian PatientsClinical Neuropharmacology, 1996
- Effect of Entacapone, a COMP Inhibitor, on the Pharmacokinetics and Metabolism of Levodopa After Administration of Controlled-Release Levodopa-Carbidopa in VolunteersClinical Neuropharmacology, 1995
- Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bileEuropean Journal of Drug Metabolism and Pharmacokinetics, 1994
- Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's diseaseEuropean Journal of Clinical Pharmacology, 1993
- Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dogEuropean Journal of Drug Metabolism and Pharmacokinetics, 1993
- Treatment of Parkinson's DiseaseNew England Journal of Medicine, 1993
- Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urineJournal of Pharmaceutical and Biomedical Analysis, 1992